223 related articles for article (PubMed ID: 19838209)
1. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.
Sachdev D; Zhang X; Matise I; Gaillard-Kelly M; Yee D
Oncogene; 2010 Jan; 29(2):251-62. PubMed ID: 19838209
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.
Zeng X; Sachdev D; Zhang H; Gaillard-Kelly M; Yee D
Clin Cancer Res; 2009 Apr; 15(8):2840-9. PubMed ID: 19351773
[TBL] [Abstract][Full Text] [Related]
3. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.
Sachdev D; Hartell JS; Lee AV; Zhang X; Yee D
J Biol Chem; 2004 Feb; 279(6):5017-24. PubMed ID: 14615489
[TBL] [Abstract][Full Text] [Related]
4. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
7. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
8. Ezrin expression and cell survival regulation in colorectal cancer.
Leiphrakpam PD; Rajput A; Mathiesen M; Agarwal E; Lazenby AJ; Are C; Brattain MG; Chowdhury S
Cell Signal; 2014 May; 26(5):868-79. PubMed ID: 24462708
[TBL] [Abstract][Full Text] [Related]
9. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
[TBL] [Abstract][Full Text] [Related]
10. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
[TBL] [Abstract][Full Text] [Related]
11. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
Tognon CE; Somasiri AM; Evdokimova VE; Trigo G; Uy EE; Melnyk N; Carboni JM; Gottardis MM; Roskelley CD; Pollak M; Sorensen PH
Cancer Res; 2011 Feb; 71(3):1060-70. PubMed ID: 21148487
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of breast cancer growth and metastasis by a biomimetic peptide.
Lee E; Lee SJ; Koskimaki JE; Han Z; Pandey NB; Popel AS
Sci Rep; 2014 Nov; 4():7139. PubMed ID: 25409905
[TBL] [Abstract][Full Text] [Related]
13. Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.
Geoerger B; Brasme JF; Daudigeos-Dubus E; Opolon P; Venot C; Debussche L; Vrignaud P; Vassal G
Eur J Cancer; 2010 Dec; 46(18):3251-62. PubMed ID: 20591650
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
Fagan DH; Uselman RR; Sachdev D; Yee D
Cancer Res; 2012 Jul; 72(13):3372-80. PubMed ID: 22573715
[TBL] [Abstract][Full Text] [Related]
15. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer.
Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883
[TBL] [Abstract][Full Text] [Related]
17. CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy.
Rostoker R; Ben-Shmuel S; Rashed R; Shen Orr Z; LeRoith D
Breast Cancer Res; 2016 May; 18(1):51. PubMed ID: 27179633
[TBL] [Abstract][Full Text] [Related]
18. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells.
Zhang H; Sachdev D; Wang C; Hubel A; Gaillard-Kelly M; Yee D
Breast Cancer Res Treat; 2009 Mar; 114(2):277-85. PubMed ID: 18418709
[TBL] [Abstract][Full Text] [Related]
19. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ
J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468
[TBL] [Abstract][Full Text] [Related]
20. Pygenic Acid A (PA) Sensitizes Metastatic Breast Cancer Cells to Anoikis and Inhibits Metastasis In Vivo.
Lim GE; Sung JY; Yu S; Kim Y; Shim J; Kim HJ; Cho ML; Lee JS; Kim YN
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
